BRAINSTORM CELL THERAPEUTICS INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that BRAINSTORM CELL THERAPEUTICS INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Net Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.11M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.90M) | Aug 14, 2025 |
| Q3 | 2025 | Jun 30, 2025 | ($2.90M) | Nov 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($2.86M) | May 15, 2025 |
| Q3 | 2025 | Mar 31, 2025 | ($2.86M) | Nov 14, 2025 |
| Q2 | 2025 | Mar 31, 2025 | ($2.86M) | Aug 14, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($2.71M) | Nov 14, 2025 |
| Q3 | 2025 | Jun 30, 2024 | ($2.54M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.54M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($3.40M) | May 15, 2025 |
| Q2 | 2025 | Mar 31, 2024 | ($3.40M) | Aug 14, 2025 |
| Q3 | 2025 | Mar 31, 2024 | ($3.40M) | Nov 14, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($1.23M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.33M) | Aug 14, 2024 |
| Q3 | 2024 | Jun 30, 2023 | ($5.33M) | Nov 14, 2024 |
| Q3 | 2024 | Mar 31, 2023 | ($5.06M) | Nov 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.06M) | May 14, 2024 |
| Q2 | 2024 | Mar 31, 2023 | ($5.06M) | Aug 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($6.86M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.04M) | Aug 14, 2023 |
Operating Income — By Quarter
| Quarter | Fiscal Year | Period End | Value | Filed |
|---|---|---|---|---|
| Q3 | 2025 | Sep 30, 2025 | ($2.05M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2025 | ($2.57M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2025 | ($3.09M) | May 15, 2025 |
| Q3 | 2025 | Sep 30, 2024 | ($3.05M) | Nov 14, 2025 |
| Q2 | 2025 | Jun 30, 2024 | ($2.98M) | Aug 14, 2025 |
| Q1 | 2025 | Mar 31, 2024 | ($2.47M) | May 15, 2025 |
| Q3 | 2024 | Sep 30, 2023 | ($6.04M) | Nov 14, 2024 |
| Q2 | 2024 | Jun 30, 2023 | ($5.45M) | Aug 14, 2024 |
| Q1 | 2024 | Mar 31, 2023 | ($5.15M) | May 14, 2024 |
| Q3 | 2023 | Sep 30, 2022 | ($6.84M) | Nov 14, 2023 |
| Q2 | 2023 | Jun 30, 2022 | ($7.59M) | Aug 14, 2023 |
| Q1 | 2023 | Mar 31, 2022 | ($5.48M) | May 15, 2023 |
| Q3 | 2022 | Sep 30, 2021 | ($5.28M) | Nov 14, 2022 |
| Q2 | 2022 | Jun 30, 2021 | ($6.12M) | Aug 15, 2022 |
| Q1 | 2022 | Mar 31, 2021 | ($6.93M) | May 16, 2022 |
| Q3 | 2021 | Sep 30, 2020 | ($4.49M) | Nov 15, 2021 |
| Q2 | 2021 | Jun 30, 2020 | ($7.40M) | Aug 5, 2021 |
| Q1 | 2021 | Mar 31, 2020 | ($8.31M) | Apr 26, 2021 |
| Q3 | 2020 | Sep 30, 2019 | ($5.55M) | Oct 15, 2020 |
| Q2 | 2020 | Jun 30, 2019 | ($4.86M) | Aug 5, 2020 |